Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Clostridioides difficile is a Gram-positive, anaerobic, spore-forming bacterium that can colonize the human gut. Non-toxigenic strains lack the genes encoding toxins A and B (tcdA/tcdB) and binary toxin (cdtAB), and do not cause disease. They are being investigated as potential therapeutic agents for preventing or inhibiting colonization by toxigenic strains through competitive exclusion and other mechanisms such as nutrient competition, bile acid modification, and production of inhibitory metabolites. They are being developed as live biotherapeutics to restore microbial balance and prevent recurrent CDI.
Competitive exclusion; nutrient competition; modification of bile acids to inhibit C. difficile spore germination and growth; production of inhibitory metabolites; inhibition of adhesion to intestinal epithelial cells.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Clostridioides difficile (non-toxigenic strain) (Non-toxigenic C. difficile).